pieris.com (PIRS): Net earnings per share growth forecast for next year
Pieris Pharmaceuticals (PIRS) relies on patented protein scaffolds for long-term B2B contracts. Innovative cancer and lung treatments are forming the foundation of future medicine. However, the company is currently cutting costs and seeking new strategies due to a lack of cash flows. The annual EPS forecast demonstrates volatility, with the metric standing at -27.50, necessitating caution when analyzing expected earnings.
Metric breakdowns and analytics for Pieris Pharmaceuticals Inc (PIRS)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Capital Pieris Pharmaceuticals|PIRS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Pieris|PIRS - Aggregate Debt Obligations|Debts to Book Capitalization Pieris Pharma|PIRS - Long-Term Debt Volume|Company Short-Term Debt Pieris Pharmaceuticals|Quick Liquidity Indicator pieris.com
- net income and valuation ratios data:
PIRS - Final Profit|Expected Profit Pieris Pharmaceuticals|PIRS - Market Cap to Net Income|Forward P/E Multiple Pieris Pharmaceuticals, Inc.|PIRS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Pieris Pharmaceuticals, Inc.|PIRS - Operating profit EBITDA|Earnings per share for the last twelve months Pieris Pharmaceuticals|PIRS - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months pieris.com|PIRS - Net earnings per share growth this year|Earnings growth forecast for next year Pieris Pharmaceuticals
- sales revenue and business income indicators:
Fundamental company valuation:pieris.com, PIRS
This indicator reflects the consensus forecast for next year's earnings growth, filtering out short-term market noise to identify the true trajectory of institutional capital. By analyzing the forward-looking assessment of net income dynamics, investors can gauge the sensitivity of Pieris Pharmaceuticals (PIRS) valuation to the commercialization of unique anticalin proteins, which establish a high patent barrier and determine the company's attractiveness for strategic partnerships with big pharma behemoths.
Competitor analysis
Net earnings per share growth forecast for next year Haleon plc|Expected net earnings per share growth next year kenvue.com KVUE|Net earnings per share growth forecast for next year Verona Pharma (VRNA)|MENS (Jyong Biotech Limited) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand Pharma LGND|Earnings growth forecast for next year Amneal Corp AMRX|Perrigo Company PLC - Earnings growth forecast for next year|ALVO: Net earnings per share growth forecast for next year|liquidia.com (LQDA) - Net earnings per share growth forecast for next year|GLPG (Galapagos) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year ANIP|Projected earnings per share growth rate for next year MNKD (Afrezza)|Earnings growth forecast for next year AMPH|PCRX (Pacira BioSciences) - Expected earnings per share trend next year|Earnings growth forecast for next year SPRY (ARS Pharmaceuticals, Inc.)|Theravance Biopharma, Inc. - Net earnings per share growth forecast for next year|Aquestive Corp - Earnings growth forecast for next year|scpharmaceuticals.com (SCPH) - Expected earnings per share growth for next year|TECX: Earnings growth forecast for next year|Tonix Pharmaceuticals - Expected earnings per share trend next year|Expected earnings per share growth for next year SXTC|EPRX: Expected earnings per share trend next year|Expected earnings per share growth for next year BHST (BioHarvest Sciences Inc.)|Consensus forecast of earnings per share growth for next year Invizyne|Net earnings per share growth forecast for next year Oramed Pharmaceuticals ORMP|Expected earnings per share trend next year ENTX|HYFT - Net earnings per share growth forecast for next year|Expected earnings per share trend next year ABVC (ABVC BioPharma Inc.)|CPIX: Earnings growth forecast for next year|Quantum BioPharma Limited - Expected earnings per share trend next year|FGEN (FibroGen Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year Telomir Pharmaceuticals|Earnings growth forecast for next year RANI|SNYR (Synergy CHC Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year RLYB (Rallybio Corp)|LEXX: Projected earnings per share growth rate for next year|PULM - Net earnings per share growth forecast for next year|PTHL: Net earnings per share growth forecast for next year|APM (aptorumgroup.com) - Expected earnings per share growth for next year|Lyra Therapeutics - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Impact BioMedical Inc|TNF Pharmaceuticals, Inc. (TNFA) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year YCBD|PRFX: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year altamiratherapeutics.com CYTO|Earnings growth forecast for next year Lipella Pharmaceuticals Inc LIPO|OPTN - Net earnings per share growth forecast for next year|Procaps Group Corp (PROC) - Expected earnings per share growth for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year QLI (Qilian International)|Expected earnings per share growth for next year SLRN|TFF Pharmaceuticals, Inc. - Net earnings per share change forecast for next year
